BioCentury
ARTICLE | Company News

Shionogi terminates pain deal with Egalet

December 5, 2015 2:09 AM UTC

Egalet Corp. (NASDAQ:EGLT) said it would regain rights to abuse-deterrent pain candidate AD ER hydrocodone ( S-718632) after Shionogi & Co. Ltd. (Tokyo:4507) terminated the companies' 2013 deal to develop and commercialize abuse-deterrent analgesics. Egalet said Shionogi had reprioritized internal development programs.

AD ER hydrocodone has completed a Phase I study and Egalet said it is evaluating future development of the program. Egalet spokesperson Blair Clark-Schoeb told BioCentury the company may seek a new partner. ...